NAS:REGN (USA)
Business Description
Regeneron Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Compare
Compare
Traded in other countries / regions
REGN.Austria
•
REGN34.Brazil
•
RGO.Germany
•
REGN.Mexico
•
REGN.Switzerland
•
0R2M.UK
•
REGN.USA
Description
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer, and bispecific antibodies and antibody cocktails with other collaborators and independently.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.8 | |||||
| Equity-to-Asset | 0.76 | |||||
| Debt-to-Equity | 0.13 | |||||
| Debt-to-EBITDA | 0.4 | |||||
| Interest Coverage | 128.73 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 9.08 | |||||
| Beneish M-Score | -2.86 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 47.3 | |||||
| 3-Year EBITDA Growth Rate | 53.6 | |||||
| 3-Year EPS without NRI Growth Rate | 50.1 | |||||
| 3-Year FCF Growth Rate | 54.5 | |||||
| 3-Year Book Growth Rate | 29.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | 1.68 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | -3.31 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 76.06 | |||||
| 9-Day RSI | 65.57 | |||||
| 14-Day RSI | 58.73 | |||||
| 6-1 Month Momentum % | -4.24 | |||||
| 12-1 Month Momentum % | -0.98 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.12 | |||||
| Quick Ratio | 4.39 | |||||
| Cash Ratio | 2.49 | |||||
| Days Inventory | 348.27 | |||||
| Days Sales Outstanding | 146.17 | |||||
| Days Payable | 84.39 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.1 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 84.97 | |||||
| Operating Margin % | 49.77 | |||||
| Net Margin % | 39.97 | |||||
| ROE % | 30.99 | |||||
| ROA % | 22.9 | |||||
| ROIC % | 38.99 | |||||
| ROC (Joel Greenblatt) % | 74.2 | |||||
| ROCE % | 29.98 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 12.25 | |||||
| Forward PE Ratio | 14.86 | |||||
| PE Ratio without NRI | 12.25 | |||||
| Shiller PE Ratio | 28.12 | |||||
| Price-to-Owner-Earnings | 11.34 | |||||
| PEG Ratio | 0.31 | |||||
| PS Ratio | 4.9 | |||||
| PB Ratio | 3.25 | |||||
| Price-to-Tangible-Book | 3.25 | |||||
| Price-to-Free-Cash-Flow | 8.86 | |||||
| Price-to-Operating-Cash-Flow | 8.24 | |||||
| EV-to-EBIT | 9.69 | |||||
| EV-to-Forward-EBIT | 10.76 | |||||
| EV-to-EBITDA | 9.26 | |||||
| EV-to-Forward-EBITDA | 10.13 | |||||
| EV-to-Revenue | 4.36 | |||||
| EV-to-Forward-Revenue | 5.25 | |||||
| EV-to-FCF | 7.88 | |||||
| Price-to-Projected-FCF | 1.24 | |||||
| Price-to-Median-PS-Value | 0.52 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.49 | |||||
| Price-to-Graham-Number | 1.33 | |||||
| Price-to-Net-Current-Asset-Value | 7.46 | |||||
| Price-to-Net-Cash | 64.12 | |||||
| Earnings Yield (Greenblatt) % | 10.32 | |||||
| Forward Rate of Return (Yacktman) % | 24.21 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:REGN
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 14,226.8 | ||
| EPS (TTM) ($) | 50.1 | ||
| Beta | 0.12 | ||
| Volatility % | 29 | ||
| 14-Day RSI | 58.73 | ||
| 14-Day ATR ($) | 18.393922 | ||
| 20-Day SMA ($) | 594.9665 | ||
| 12-1 Month Momentum % | -0.98 | ||
| 52-Week Range ($) | 538.01 - 747.4214 | ||
| Shares Outstanding (Mil) | 109.01 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Regeneron Pharmaceuticals Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||